VYNE Therapeutics (NASDAQ:VYNE) Stock Price Up 0.4% – Still a Buy?

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) rose 0.4% during trading on Monday . The company traded as high as $0.6185 and last traded at $0.6037. Approximately 170,707 shares were traded during trading, a decline of 7% from the average daily volume of 183,039 shares. The stock had previously closed at $0.6010.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on VYNE shares. Wall Street Zen raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, VYNE Therapeutics currently has an average rating of “Reduce” and an average price target of $4.50.

VYNE Therapeutics Price Performance

The stock has a market capitalization of $20.33 million, a PE ratio of -0.78 and a beta of 1.94. The business’s fifty day moving average price is $0.59 and its 200-day moving average price is $0.49.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.The firm had revenue of $0.13 million during the quarter. On average, analysts expect that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Anson Funds Management LP bought a new position in shares of VYNE Therapeutics in the fourth quarter worth $739,000. Nantahala Capital Management LLC bought a new position in shares of VYNE Therapeutics in the fourth quarter worth $580,000. T3 Companies LLC bought a new position in shares of VYNE Therapeutics in the fourth quarter worth $548,000. Baker BROS. Advisors LP bought a new position in shares of VYNE Therapeutics in the third quarter worth $285,000. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the period. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.